KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing...

KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.

Read article

What are you looking for?

6 June 2022
JSR Corporation

JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Valu...

JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.

3 June 2022
JSR Corporation

JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.

JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.

12 May 2022
Crown Bioscience

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanes...

Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

11 May 2022
Selexis

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this r...

10 May 2022
JSR Life Sciences

JSR Life Sciences Launches ‘Similis Bio’ to Help Partners Accelerate Biosimilar Development

Newly launched business line leverages the combined experience and technical knowledge of leaders in analytical, cell-line, and process development to reduce up-front time and resource co...

2 May 2022
KBI Biopharma

JSR Life Sciences Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead...

Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the US.

View news archive

14 June 2022
KBI Biopharma

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing...

KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Swi...

6 June 2022
JSR Corporation

JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Valu...

JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.

3 June 2022
JSR Corporation

JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.

JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.

12 May 2022
Crown Bioscience

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanes...

Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

11 May 2022
Selexis

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this r...

10 May 2022
JSR Life Sciences

JSR Life Sciences Launches ‘Similis Bio’ to Help Partners Accelerate Biosimilar Development

Newly launched business line leverages the combined experience and technical knowledge of leaders in analytical, cell-line, and process development to reduce up-front time and resource co...

View news archive

12 May 2022
Crown Bioscience

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanes...

Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

28 April 2022
Crown Bioscience

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer...

Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which pr...

8 December 2021
Crown Bioscience

Crown Bioscience Expands UK Facilities to Enable Growth of In Vivo Services

Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the company’s preclinical capabilities

7 December 2021
Crown Bioscience

Crown Bioscience Expands UK Facilities to Enable Growth of In Vivo Services

Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the Company’s preclinical capabilities

26 October 2021
Crown Bioscience

Crown Bioscience Unveils New Identity

The new brand reinforces the company’s commitment to the power of partnership and the infinite possibilities of scientific innovation

7 October 2021
Crown Bioscience

Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Response Predictability...

Platform combining phenotypic high content imaging analysis and three-dimensional models of fresh patient tumors to provide relevant analysis of drug responses that can inform candidate s...

View news archive

14 June 2022
KBI Biopharma

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing...

KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Swi...

11 May 2022
Selexis

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this r...

19 January 2022
Selexis

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Pr...

Selexis and Inotrem have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations

12 January 2022
Selexis

Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CD...

Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and modular workflows

29 June 2021
KBI Biopharma

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance ...

Selexis and KBI announced today that they have signed service agreements with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redire...

23 March 2021
Selexis

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies...

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements

View news archive

14 June 2022
KBI Biopharma

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing...

KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Swi...

2 May 2022
KBI Biopharma

JSR Life Sciences Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead...

Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the US.

21 April 2022
KBI Biopharma

KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility

KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park...

10 March 2022
KBI Biopharma

Oragenics Engages KBI Biopharma to Support Development of the Intranasal COVID-19 Vaccine Candida...

KBI to Produce Material for Use in Upcoming Phase 2 Clinical Trial of Oragenics’ Intranasal Vaccine Candidate

11 October 2021
KBI Biopharma

KBI Biopharma Completes Eurofins DiscoverX Products Specialized Bioassay Certification Program

Companies will work together on critical components that can accelerate client-sponsored validation programs through downstream drug development

1 July 2021
KBI Biopharma

Adalta Secures AD-214 Resupply Under KBI Biopharma MSA

The clinical resupply services will be delivered under AdAlta’s contract development and manufacturing Master Services Agreement with KBI Biopharma that was announced on 5 June 2018.

View news archive

12 May 2022
Crown Bioscience

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanes...

Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

11 April 2022
MBL

MBL Launches Five-test Kit for Rapid SARS-CoV-2 Antigen Detection

This product is a five-test kit version of GLINE-2019-nCoV Ag Kit (Code No. YH-G86256) which was released on February 14th as a one test kit

4 April 2022
MBL

Launch of a New Kit for the Detection of Anti-Integrin αvβ6 Antibodies for Understanding Patholog...

Anti-integrin αvβ6 antibodies are detected in about 90% of UC patients, and the results of basic research suggest that these autoantibodies themselves may be causing the disease

3 March 2022
MBL

MBL Donated 20,000 SARS-CoV-2 Antigen Test Kits to Ina City, Nagano Prefecture in Japan

MBL donated 20,000 their SARS-CoV-2 antigen test kits "GLINE-2019-nCoV Ag kit" to Ina City, Nagano Prefecture, where their research and production facilities are located

11 February 2022
MBL

Acquisition of Manufacturing and Marketing Approval for SARS-CoV-2 Antigen Rapid Test and Release...

With a simple operation, the presence or absence of the SARS-CoV-2 antigen can be determined in 15 minutes

26 January 2022
MBL

MBL Announces IVD Product Certification for MEBGEN AZF Deletion Kit for the Japanese Market

The kit is designed to detect the presence or absence of AZF deletion and the type of AZF deletion in Japanese men prior to microdissection testicular sperm extraction for male infertility

View news archive

6 June 2022
JSR Corporation

JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Valu...

JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.

3 June 2022
JSR Corporation

JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.

JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.

13 April 2022
JSR Corporation

JSR and Asahi Kasei Medical Enter Co-promotion Agreement

JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated ...

16 March 2021
JSR Corporation

JSR Life Sciences Completes Integration of MBL into its Family of Companies

JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Scie...

20 September 2019
JSR Corporation

PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity ...

The development will be based on PeptiDream’s proprietary drug discovery platform, PDPS (Peptide Discovery Platform System), and JSR’s extensive knowledge of affinity separation technology.